NCT06728670 Pharmacokinetic Study of Tranexamic Acid
| NCT ID | NCT06728670 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhejiang Cancer Hospital |
| Condition | Ovarian Neoplasm Epithelial |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-11-20 |
| Primary Completion | 2025-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-11-20 with a primary completion date of 2025-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Tranexamic acid is an effective anti fibrinolytic drug. Clinical studies have found that intravenous injection of tranexamic acid is more effective in reducing blood loss and transfusion in patients with advanced ovarian cancer, without increasing the risk of postoperative complications. Different surgeries and administration routes have an impact on the pharmacokinetics and pharmacodynamics of TXA. At present, there is little data on the pharmacokinetics of intramuscular injection of TXA, and almost all of the data comes from males. For ovarian cancer patients, there are currently no reports on the pharmacokinetics of TXA through different routes of administration, such as intramuscular and intravenous administration. Therefore, the investigators chose ovarian cancer patients and administered it through different routes of intravenous and intramuscular injection.
Eligibility Criteria
Inclusion Criteria: 1. Adult women aged 20-64 diagnosed with advanced ovarian cancer undergoing cytoreductive surgery 2. The cancer stage is III-IV 3. ASA classification II-III 4. Surgical duration\>2 hours Exclusion Criteria: 1. Renal dysfunction (serum creatinine\>200 mmol/L) or liver dysfunction (Child Turcote classification\>6) 2. Has a history of serious mental illness or disorders, epilepsy, visual impairment 3. Previous or current bleeding disorders, coagulation dysfunction, or thromboembolic events 4. Lower limb venous thrombosis 5. Anticoagulants or antifibrinolytic drugs used before surgery within the past month 6. Allergic to TXA
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06728670 clinical trial?
This trial is open to female participants only, aged 20 Years or older, up to 64 Years, studying Ovarian Neoplasm Epithelial. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06728670 currently recruiting?
Yes, NCT06728670 is actively recruiting participants. Contact the research team at zhuyejing1983@126.com for enrollment information.
Where is the NCT06728670 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06728670 clinical trial?
NCT06728670 is sponsored by Zhejiang Cancer Hospital. The trial plans to enroll 30 participants.